EMB and HIV-1 infection: Specifically, the median V1V2 IgG concentration was boosted to 9.5–20 μg/mL, which is greater than the median peak concentration measured in RV144 associated with a decrease in HIV-1 infection (at least 2.98 μg/mL gp70.B (CaseA2)-V1V2) specific IgG [35]) enabling 80% of vaccinees to achieve this level in RV305 compared to 63% in RV144.